FDA and EMA both hammer Brazilian sterile antibiotics maker over contamination concerns

Sterile manufacturing at Antibioticos Do Brasil plant in Sao Paulo.

A Brazilian antibiotics maker that was hammered in an FDA warning letter issued last month also caught the attention of the European Medicines Agency, which has banned its products because of concerns over the sterile manufacturing plant’s standards.

In fact, many of the issues noted by Italian inspectors during a December 12 inspection of the Antibioticos Do Brasil facility had been laid out in an FDA warning letter issued days before, the second for the Sao Paulo plant, which had also been cited in a 2009 FDA warning letter.

The FDA, which inspected the facility in April 2016, had noted that sterile areas didn’t have unidirectional airflow in sterile filling areas that could protect products from contamination. The agency also had concerns about other procedures to monitor for and protect aseptic filling areas from microbiological contamination. The agency recommended the company bring in experts to help it figure out how to meet standards.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Italian inspectors tallied four critical and seven major deficiencies at the plant, hammering the antibiotics maker for not keeping sterile manufacturing areas clean or safe from potential contamination.

Among the long list of problems inspectors noted was that plant employees in general didn’t seem to be trained or aware of GMP methods and there were few supervisors to oversee their work. They found the quality management system weak, data collection poor and “anomalous events had not been appropriately investigated and documented.”

The inspectors also noted that the company did not have any training on the differences in requirements for products being shipped into the EU versus the standards in Brazil.

Besides banning Antibioticos Do Brazil from shipping sterile drugs into the EU, the European Medicines Agency has suspended its certificate of manufacturing for sterile production. It said the facility would have to go through another inspection, showing the deficiencies had been corrected, to regain its status in the EU.

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.